{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination acts as a sensitizer, dramatically improving the therapeutic effect of immune checkpoint blockade (ICI) therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        },
        {
          "quote": "Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        }
      ],
      "caveat": "The human analysis is retrospective and non-randomized; residual confounding is likely."
    },
    {
      "claim_id": "C02",
      "claim": "The sensitization effect is dependent on and mediated by local type I interferon signaling, which is triggered by the mRNA platform.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.",
          "line_ref": "L42"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C03",
      "claim": "The mechanism of action involves a strong expansion of the tumor's MHC-I-presented antigen landscape, making the tumor more visible to T cells.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        },
        {
          "quote": "Interferon-associated antigen processing and presentation pathways increase.",
          "line_ref": "L43"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors."
    },
    {
      "claim_id": "C04",
      "claim": "PD-L1 pathway activity increases following vaccination, creating a stronger rationale for the combination therapy.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.",
          "line_ref": "L45"
        }
      ],
      "caveat": "ICI-only treatment had limited activity in low-immunogenic baseline settings."
    }
  ]
}